GlobeNewsWire·Oct 29, 2026
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed's revenue grew roughly 9.9% year over year on a trailing basis, with gross margin holding in a 57.6% to 62.2% band over ten quarters, suggesting durable demand and pricing discipline.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth of roughly 9.9% and a gross margin band of 57.6% to 62.2% suggest resilient top-line momentum and pricing discipline, although the latest quarter's 58.8% gross margin and 26.2% net margin warrant monitoring for early compression.
ResMed provides cutting-edge medical devices and cloud-connectable solutions for sleep apnea and respiratory conditions like COPD, improving patient outcomes.
ResMed is a leader in the CPAP industry, known for its innovative, user-friendly, and comfortable products that are trusted worldwide.
The company has a wide moat, supported by its strong brand, innovative technology, and leadership in the sleep apnea and respiratory care markets.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $2.91+8.2% vs $2.69 | $1.4B+1.5% vs $1.4B |
Q3 2026 Aug 6, 2026 | $2.95+2.1% vs $2.89 | $1.5B+0.2% vs $1.5B |
Q2 2026 Apr 30, 2026 | $2.86+2.1% vs $2.80 | $1.4B+0.8% vs $1.4B |
Q1 2026 Jan 29, 2026 | $2.81+2.6% vs $2.74 | $1.4B+1.6% vs $1.4B |
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Benchmark RMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ResMed Inc. (RMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $235.30 | $34.13B | 21.18 | 9.85% | 27.79% | 25.14% | 1.03% | |
| $30.35 | $29.66B | 28.16 | -1.04% | 5.4% | 8.37% | 1.25% | |
| $126.56 | $4.3B | 42.23 | 7.57% | 5.68% | 6.02% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $63.98 | $1.84B | 18.38 | 13.6% | 11.43% | 12.49% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — |
ResMed Inc. (RMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ResMed Inc. (RMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Aug 17, 2026·SEC
Aug 6, 2026·SEC
Get notified when RMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ResMed Inc. (RMD) stock FAQ — growth, dividends, profitability & financials explained
ResMed Inc. (RMD) reported $5.73B in revenue over the trailing twelve months. Revenue was $5.65B in fiscal year 2026. That is 11391% more than the $49.2M of fiscal year 1997.
ResMed Inc. (RMD) grew revenue by 9.0% over the trailing twelve months, compared with the twelve months before.
Yes. ResMed Inc. (RMD) earned $1.59B in net income over the trailing twelve months (a 27.8% net margin).
Yes. ResMed Inc. (RMD) pays a dividend that yields 1.03% at the current price, a moderate yield.
ResMed Inc. (RMD) had a return on equity (ROE) of 25.1% over the trailing twelve months. That is well above the market's typical 10-15%.
ResMed Inc. (RMD) generated $2.85B in free cash flow over the trailing twelve months.
